Company Overview and News
2018-09-24 zacks - 3
TransEnterix, Inc. (TRXC - Free Report) recently announced that it has acquired Israel-based MST Medical Surgery Technologies Ltd. The acquisition is likely to strengthen the Senhance platform by boosting effectiveness of surgeons as well as making procedures quicker and error free.
MASI VEEV TRXC ATHN TITN
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")[email protected],0G?08F1H8#(%D&1G3B/^/D/P [email protected]"[email protected];D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
2018-09-05 seekingalpha - 11
While much attention is being riveted on the S&P 500's new all-time high eclipsing the January one, small caps accomplished that in May.
VRTX ECYT VSTM TRXC VKTX ENL CVS LGNDZ RGNX IMMU BIIB LGNYZ REGI HRTX NVTA NBIX ARWR SRPT ICPT VKTXW XLRN FNKO MRTX LGNZZ LGND NVS HEAR LGNXZ NTRA UNH PFE ENDP
2018-08-07 seekingalpha - 8
Good morning, ladies and gentlemen. Welcome to the TransEnterix Second Quarter's Financial and Operating Results Conference Call. As a reminder, this conference call is webcast live and recorded.
HTGZ HTGC TRXC HTGX HTGY
2018-08-07 zacks - 4
TransEnterix (TRXC - Free Report) just came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
AMT TRXC NHI BCRX GTLS
2018-07-29 seekingalpha - 9
Robotic surgery represents the next wave of surgical innovation. Increasing industry tailwind supports the improving bottom line for surgical robotic innovators.
TRXC ISRG MZOR MDT
2017-11-07 - Asif
TransEnterix, Inc. is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical challenges associated with current laparoscopic and robotic options. TransEnterix is focused on the commercialization and further development of its Senhance™ Surgical Robotic System (formerly known as the ALF-X ® Surgical Robotic System) (the “Senhance System”), a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology. The Senhance System has been granted a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, but is not available for sale in the U.S. TransEnterix has also developed the SurgiBot™ System (the “SurgiBot System”), a single-port, robotically enhanced laparoscopic surgical platform. The SurgiBot System is not available for sale in any market. The Senhance...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TRXC / TransEnterix, Inc. on message board site Silicon Investor.
|TRXC TransEnterix||TRXC TransEnterix||TRXC TransEnterix|
as of ET